Form 4: Vaxcyte COO Jim Wassil Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, sold a portion of his common stock holdings on August 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. (PCVX), sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 23, 2023.
• A total of 3,000 shares were sold in two transactions.
• 2,977 shares were sold at a weighted-average price of $78.8375, with individual prices ranging from $78.28 to $79.23.
• An additional 23 shares were sold at a price of $79.47.
• Following the reported transactions, Wassil beneficially owns 207,503 shares of Vaxcyte common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider selling can be interpreted in various ways by the market. While sales under a 10b5-1 plan are pre-scheduled and often don't reflect a change in the executive's outlook for the company, investors may still react to the news.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the pre-planned nature of the sales mitigates potential negative interpretations.
• Employees may be indirectly affected by any market reaction to the news.

Key Dates